Standard Biotools Inc. (LAB) — SEC Filings
Standard Biotools Inc. (LAB) — 50 SEC filings. Latest: 10-Q (Nov 4, 2025). Includes 22 8-K, 6 10-Q, 6 SC 13G/A.
View Standard Biotools Inc. on SEC EDGAR
Overview
Standard Biotools Inc. (LAB) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 4, 2025: STANDARD BIOTOOLS INC. (LAB) reported a net loss of $34.687 million for the three months ended September 30, 2025, an increase from a net loss of $26.938 million in the same period of 2024. Total revenue decreased by 11.47% to $19.552 million in Q3 2025 from $22.086 million in Q3 2024, driven by dec
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral, 1 mixed. The dominant filing sentiment for Standard Biotools Inc. is neutral.
Filing Type Overview
Standard Biotools Inc. (LAB) has filed 6 10-Q, 22 8-K, 1 DEF 14A, 2 10-K, 6 SC 13G/A, 5 SC 13G, 5 SC 13D/A, 1 DEFA14A, 1 10-K/A, 1 8-K/A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of LAB's 35 recent filings, 1 were flagged as high-risk, 20 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $19.552M |
| Net Income | -$34.687M |
| EPS | -$0.09 |
| Cash Position | $129.418M |
Key Executives
- Dr. Jonathan M. Rothberg
- Mr. David E. R. King
- Mr. David E. R. Harding
- Ms. Sarah H. Harrington
- Mr. Michael A. G. Johnson
- Mr. David J. E. King
- Eli Casdin
- Mr. David E. R. Gross
Industry Context
The biotechnology tools sector is highly competitive and capital-intensive, often characterized by long development cycles and significant R&D investment. Companies like STANDARD BIOTOOLS INC. face pressure from both established players and emerging innovators. Recent trends indicate a growing demand for advanced diagnostic and research tools, but also increasing scrutiny on profitability and operational efficiency.
Top Tags
8-K (5) · 10-Q (5) · financial-reporting (5) · governance (5) · financials (4) · corporate-governance (4) · restructuring (3) · biotechnology (3) · disclosure (3) · ownership-change (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Total Revenue (Q3 2025) | $19.552M | Decreased from $22.086M in Q3 2024, an 11.47% decline. |
| Net Loss (Q3 2025) | $34.687M | Widened from $26.938M in Q3 2024. |
| Restructuring and Related Charges (Q3 2025) | $9.428M | Increased significantly from $2.341M in Q3 2024, a 302.73% jump. |
| Cash and Cash Equivalents (Sept 30, 2025) | $129.418M | Decreased from $166.728M at Dec 31, 2024. |
| Net Cash Used in Operating Activities (9 months ended Sept 30, 2025) | $73.153M | Indicates significant cash burn. |
| Net Loss Per Share (Q3 2025) | $0.09 | Increased from $0.07 in Q3 2024. |
| Common Stock Shares Outstanding (Nov 2, 2025) | 384,565,414 | Reflects total shares outstanding. |
| Fiscal Quarter End | Q2 --12-31 | Indicates the reporting period for the 10-Q |
| Reporting Period End | 2025-06-30 | Specific date for the financial data presented |
| Filing Date | 2025-08-15 | Date the report was officially submitted to the SEC |
| Reporting Period | Q1 2025 | First quarter of 2025 financial data |
| Fiscal Year End | 1231 | Indicates the end of the company's fiscal year |
| Meeting Date | 20250618 | The date of the annual shareholder meeting for which this proxy statement is issued. |
| SEC File Number | 001-34180 | Identifies the company's filing with the SEC. |
| IRS Employer Identification Number | 77-0513190 | Company's tax identification number. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Standard Biotools Inc. (LAB)?
Standard Biotools Inc. has 50 recent SEC filings from Jan 2024 to Nov 2025, including 22 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of LAB filings?
Across 50 filings, the sentiment breakdown is: 2 bullish, 1 bearish, 46 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Standard Biotools Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Standard Biotools Inc. (LAB) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Standard Biotools Inc.?
Key financial highlights from Standard Biotools Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for LAB?
The investment thesis for LAB includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Standard Biotools Inc.?
Key executives identified across Standard Biotools Inc.'s filings include Dr. Jonathan M. Rothberg, Mr. David E. R. King, Mr. David E. R. Harding, Ms. Sarah H. Harrington, Mr. Michael A. G. Johnson and 3 others.
What are the main risk factors for Standard Biotools Inc. stock?
Of LAB's 35 assessed filings, 1 were flagged high-risk, 20 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Standard Biotools Inc.?
Forward guidance and predictions for Standard Biotools Inc. are extracted from SEC filings as they are enriched.